Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complex brain networks: graph theoretical analysis of structural and functional systems
Bullmore, E., & Sporns, O. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2575 · Cited by 11,820
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“Df(16)A , Lgdel and Df1 mice are mutant mice with deletions of mouse chromosome 16, which models a microdeletion on human chromosome 22q11.”
BackgroundKapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
Neurocognitive deficit in schizophrenia: A quantitative review of the evidence.
Heinrichs, R. W., & Zakzanis, K. K. (1998) · Neuropsychology · doi:10.1037/0894-4105.12.3.426 · Cited by 2,798
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
The environment and schizophrenia
van Os, J., Kenis, G., & Rutten, B. P. F. (2010) · Nature · doi:10.1038/nature09563 · Cited by 1,572
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
Green, M. F., Kern, R. S., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.009 · Cited by 1,422
Medial Frontal Cortex Mediates Perceptual Attentional Set Shifting in the Rat
Birrell, J. M., & Brown, V. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04320.2000 · Cited by 1,421
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
GABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder
Benes, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00225-1 · Cited by 1,082
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Gogos, J. A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D., & Karayiorgou, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9991 · Cited by 864
Fone, K. C. F., & Porkess, M. V. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.003 · Cited by 864
Kirov, G., Pocklington, A. J., Holmans, P., Ivanov, D., Ikeda, M., Ruderfer, D., Moran, J., Chambert, K., Toncheva, D., Georgieva, L., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.154 · Cited by 844
Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.514 · Cited by 744
Impaired hippocampal–prefrontal synchrony in a genetic mouse model of schizophrenia
Sigurdsson, T., Stark, K. L., Karayiorgou, M., Gogos, J. A., & Gordon, J. A. (2010) · Nature · doi:10.1038/nature08855 · Cited by 702
The environment and susceptibility to schizophrenia
Brown, A. S. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.003 · Cited by 664
Negative Symptoms in Schizophrenia: Avolition and Occam's Razor
Foussias, G., & Remington, G. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn094 · Cited by 594
Fuchs, E. C., Zivkovic, A. R., Cunningham, M. O., Middleton, S., LeBeau, F. E. N., Bannerman, D. M., Rozov, A., Whittington, M. A., Traub, R. D., Rawlins, J. N. P., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.031 · Cited by 532
Behavioral phenotypes of Disc1 missense mutations in mice
Clapcote, S. J., Lipina, T. V., Millar, J. K., Mackie, S., Christie, S., Ogawa, F., Lerch, J. P., Trimble, K., Uchiyama, M., Sakuraba, Y., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.04.015 · Cited by 526
Kellendonk, C., Simpson, E. H., Polan, H. J., Malleret, G., Vronskaya, S., Winiger, V., Moore, H., & Kandel, E. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.023 · Cited by 520
Korotkova, T., Fuchs, E. C., Ponomarenko, A., von Engelhardt, J., & Monyer, H. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.017 · Cited by 480
Gonzalez-Burgos, G., & Lewis, D. A. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs010 · Cited by 478
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426
Sams-Dodd, F., Lipska, B. K., & Weinberger, D. R. (1997) · Psychopharmacology · doi:10.1007/s002130050349 · Cited by 346
Haenschel, C., Bittner, R. A., Waltz, J., Haertling, F., Wibral, M., Singer, W., Linden, D. E. J., & Rodriguez, E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1428-09.2009 · Cited by 303
Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology
Abazyan, B., Nomura, J., Kannan, G., Ishizuka, K., Tamashiro, K. L., Nucifora, F., Pogorelov, V., Ladenheim, B., Yang, C., Krasnova, I. N., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.022 · Cited by 255
Understanding the Role of DISC1 in Psychiatric Disease and during Normal Development
Brandon, N. J., Millar, J. K., Korth, C., Sive, H., Singh, K. K., & Sawa, A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3355-09.2009 · Cited by 198
The disconnection syndrome: Basic findings reaffirmed
Seymour, S. E., Reuter-Lorenz, P. A., & Gazzaniga, M. S. (1994) · Brain · doi:10.1093/brain/117.1.105 · Cited by 193
Chen, Y.-J. J., Johnson, M. A., Lieberman, M. D., Goodchild, R. E., Schobel, S., Lewandowski, N., Rosoklija, G., Liu, R.-C., Gingrich, J. A., Small, S., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1815-08.2008 · Cited by 188
Carlson, G. C., Talbot, K., Halene, T. B., Gandal, M. J., Kazi, H. A., Schlosser, L., Phung, Q. H., Gur, R. E., Arnold, S. E., & Siegel, S. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109625108 · Cited by 103
Potkin, S. G., Turner, J. A., Fallon, J. A., Lakatos, A., Keator, D. B., Guffanti, G., Macciardi, F., & FBIRN (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.127 · Cited by 97
Powell, S. B., Young, J. W., Ong, J. C., Caron, M. G., & Geyer, M. A. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32830dc110 · Cited by 57
Research works printed but not linked: 148
- Lieberman. J. A. & Stroup, T. S. The NIMH-CATIE Schizophrenia Study: what did we learn? Am. J. Psychiatry. 168, 770–775 (2011). · DOI
- Nasrallah, H. A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol. Psychiatry 13, 27–35 (2008). · DOI · Paper page
- Meltzer, H. Y. What's atypical about atypical antipsychotic drugs? Curr. Opin. Pharmacol. 4, 53–57 (2004). · DOI · Paper page
- Paz, R. D., Tardito, S., Atzori, M. & Tseng, K. Y. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur. Neuropsychopharmacol. 18, 773–786 (2008). · DOI · Paper page
- Adams, B. W. & Moghaddam, B. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol. Psychiatry 50, 750–757 (2001). · DOI
- Nudmamud-Thanoi S., Piyabhan P., Harte M. K., Cahir M. & Reynolds G. P. Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia. J. Neural Transm. Suppl. 72, 281–285 (2007). · DOI
- Harrison, P. J., Law, A. J. & Eastwood, S. L. Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann. NY Acad. Sci. 1003, 94–101 (2003). · DOI · Paper page
- Harrison, P. J. & Eastwood, S. L. Vesicular glutamate transporter (VGLUT) gene expression provides further evidence for glutamatergic synaptic pathology in the hippocampus in schizophrenia. Schizophr. Res. 60, S62–S63 (2003). · DOI
- Kristiansen, L. V., Huerta, I., Beneyto, M. & Meador-Woodruff, J. H. NMDA receptors and schizophrenia. Curr. Opin. Pharmacol. 7, 48–55 (2007). · DOI · Paper page
- Schwartz, T. L., Sachdeva, S. & Stahl, S. M. 'Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia'. Curr. Pharm. Des. 18, 1580–1592 (2012). · DOI
- Large, C. H. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J. Psychopharmacol. 21, 283–301 (2007). · DOI · Paper page
- Hagan, J. J. & Jones, D. N. C. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr. Bull. 31, 830–853 (2005). · DOI · Paper page
- Heekeren, K. et al. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. J. Psychopharmacol. 21, 312–320 (2007). · DOI · Paper page
- Sams-Dodd, F. Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology 135, 182–193 (1998). · DOI
- Young, J. W., Powell, S. B., Risbrough, V., Marston, H. M. & Geyer, M. A. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol. Ther. 122, 150–202 (2009). · DOI · Paper page
- Thomson, D. M., Mcvie, A., Morris, B. J. & Pratt, J. A. Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine. Psychopharmacology 213, 681–695 (2011). · DOI
- Amitai, N. & Semenova, S. & Markou, A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology 193, 521–537 (2007). · DOI
- Thomsen, M. S., Hansen, H. H., Timmerman, D. B. & Mikkelsen, J. D. Cognitive improvement by activation of α7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr. Pharm. Des. 16, 323–343 (2010). · DOI · Paper page
- Martin, L. F., Kem, W. R. & Freedman, R. α-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 174, 54–64 (2004). · DOI · Paper page
- Morein-Zamir, S., Turner, D. C. & Sahakian, B. J. A review of the effects of modafinil on cognition in schizophrenia. Schizophr. Bull. 33, 1298–1306 (2007). · DOI · Paper page
- Scoriels, L., Barnett, J. H., Soma, P. K., Sahakian, B. J. & Jones, P. B. Effects of modafinil on cognitive functions in first episode psychosis. Psychopharmacology 220, 249–258 (2012). · DOI
- Goetghebeur, P. & Dias, R. Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat — a back translational study. Psychopharmacology 202, 287–293 (2009). · DOI
- Pratt, J. A., Dawson, N., Winchester, C. L., Thomson, D. M. & Morris, B. J. Distinct aspects of prefrontal cortex dysfunction in schizophrenia modelled by acute and repeated PCP treatment: impact of modafinil. Schizophr. Res. 117, 509 (2010). · doi:10.1016/j.schres.2010.02.972
- Rodefer, J. S., Murphy, E. R. & Baxter, M. G. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur. J. Neurosci. 21, 1070–1076 (2005). · DOI · Paper page
- Hatcher, P. D. et al. 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology 181, 253–259 (2005). · DOI
- Morris, B. J., Cochran, S. M. & Pratt, J. A. PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 5, 101–106 (2005). · DOI · Paper page
- Ellenbroek, B. A. & Cools, A. R. The neurodevelopment hypothesis of schizophrenia: clinical evidence and animal models. Neurosci. Res. Commun. 22, 127–136 (1998). · DOI · Paper page
- Hayashi-Takagi, A. & Sawa, A. Disturbed synaptic connectivity in schizophrenia: convergence of genetic risk factors during neurodevelopment. Brain Res. Bull. 83, 140–146 (2010). · DOI
- Charych, E. I., Liu, F., Moss, S. J. & Brandon, N. J. GABAA receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology 57, 481–495 (2009). · DOI · Paper page
- Kim, J. Y. et al. Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia. Cell 148, 1051–1064 (2012). · DOI · Paper page
- Atack, J. R. GABAA receptor α2/α3 subtype-selective modulators as potential nonsedating anxiolytics. Curr. Top. Behav. Neurosci. 2, 331–360 (2011). · DOI
- Tseng, K. Y., Chambers, R. A. & Lipska, B. K. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav. Brain Res. 204, 295–305 (2009). · DOI · Paper page
- Becker, A., Grecksch, G., Bernstein, H. G., Hollt, V. & Bogerts, B. Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology 144, 333–338 (1999). · DOI · Paper page
- Le Pen, G. et al. Impact of chronic antipsychotic treatments on hypersensitivity to MK-801 in a neurodevelopmental model of schizophrenia. Eur. Neuropsychopharmacol. 17, S480–S481 (2007). · doi:10.1016/s0924-977x(07)70734-4
- Lodge, D. J. & Grace, A. A. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav. Brain Res. 204, 306–312 (2009). · DOI · Paper page
- Bitanihirwe, B. K. Y., Peleg-Raibstein, D., Mouttet, F., Feldon, J. & Meyer, U. Late prenatal immune activation in mice leads to behavioral abnormalities relevant to the negative symptoms of schizophrenia. Schizophr. Res. 117, 273–274 (2010). · doi:10.1016/j.schres.2010.02.439
- Ozawa, K. et al. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol. Psychiatry 59, 546–554 (2006). · DOI · Paper page
- Cardno, A. G., Rijsdijk, F. V., Gottesman, I. I. & McGuffin, P. Heritability estimates for psychotic symptom dimensions in twins with psychotic disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B, 89–98 (2011).
- Mitchell, K. J. What is complex about complex disorders? Genome Biol. 13, 237 (2012). · DOI · Paper page
- Ayhan, Y., Sawa, A., Ross, C. A. & Pletnikov, M. V. Animal models of gene–environment interactions in schizophrenia. Behav. Brain Res. 204, 274–281 (2009). · DOI · Paper page
- Arguello, P. A. & Gogos, J. A. Genetic and cognitive windows into circuit mechanisms of psychiatric disease. Trends Neurosci. 35, 3–13 (2012). · DOI
- Allen, N. C. et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature Genet. 40, 827–834 (2008). · DOI · Paper page
- Swerdlow, N. R., Geyer, M. A. & Braff, D. L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 156, 194–215 (2001). · DOI · Paper page
- van den Buuse, M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr. Bull. 36, 246–270 (2010). · DOI · Paper page
- Fitzgerald, P. J. et al. Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder? Neurobiol. Dis. 40, 608–621 (2010). · DOI · Paper page
- Bannerman, D. M. et al. NMDA receptor subunit NR2A is required for rapidly acquired spatial working memory but not incremental spatial reference memory. J. Neurosci. 28, 3623–3630 (2008). · DOI · Paper page
- Inta, D., Monyer, H., Sprengel, R., Meyer-Lindenberg, A. & Gass, P. Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review. Neurosci. Biobehav. Rev. 34, 285–294 (2010). · DOI
- Lipina, T. V. et al. Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse 65, 234–248 (2011). · DOI · Paper page
- Boulay, D. et al. Comparative phenotype in behavioral models related to schizophrenia: Disc1 (L100P) mutant, NMDA Nr1neo−/− hypomorphic and DAT−/− mice. Program No. 766.1 2010 Neuroscience Meeting Planner (San Diego, California; Society for Neuroscience, 2010).
- Shoji, H. et al. Comprehensive behavioral analysis of ENU-induced Disc1-Q131L and -L100P mutant mice. BMC Res. Notes 5, 108 (2012). · DOI
- Shen, S. et al. Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. J. Neurosci. 28, 10893–10904 (2008). · DOI · Paper page
- Kvajo, M. et al. Altered axonal targeting and short-term plasticity in the hippocampus of Disc1 mutant mice. Proc. Natl Acad. Sci. USA 108, E1349–E1358 (2011). · DOI · Paper page
- Gainetdinov, R. R. Dopamine transporter mutant mice in experimental neuropharmacology. Naunyn Schmiedebergs Arch. Pharmacol. 377, 301–313 (2008). · DOI
- Wen, L. et al. Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. Proc. Natl Acad. Sci. USA 107, 1211–1216 (2010). · DOI · Paper page
- Simpson, E. H. et al. Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia. Biol. Psychiatry 69, 928–935 (2011). · DOI · Paper page
- Pearlson, G. D. & Calhoun, V. D. Convergent approaches for defining functional imaging endophenotypes in schizophrenia. Front. Hum. Neurosci. 3, 37 (2009). · DOI · Paper page
- Braff, D. L., Freedman, R., Schork, N. J. & Gottesman, I. I. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr. Bull. 33, 21–32 (2007). · DOI · Paper page
- Callicott, J. H. et al. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am. J. Psychiatry 160, 2209–2215 (2003). · DOI · Paper page
- Potkin, S. G. et al. Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. Schizophr. Bull. 35, 19–31 (2009). · DOI · Paper page
- McIntosh, A. R., Nyberg, L., Bookstein, F. L. & Tulving, E. Differential functional connectivity of prefrontal and medial temporal cortices during episodic memory retrieval. Hum. Brain Mapp. 5, 323–327 (1997). · DOI · Paper page
- Friston, K. J. & Frith, C. D. Schizophrenia: a disconnection syndrome. Clin. Neurosci. 3, 89–97 (1995).
- Meyer-Lindenberg, A. et al. Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am. J. Psychiatry 158, 1809–1817 (2001). · DOI · Paper page
- Mcintosh, A. R. & Gonzalezlima, F. Structural modeling of functional neural pathways mapped with 2-deoxyglucose: effects of acoustic startle habituation on the auditory-system. Brain Res. 547, 295–302 (1991). · DOI · Paper page
- Dawson, N. et al. Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivity. Schizophr. Bull. 38, 457–474 (2012). · DOI · Paper page
- Cochran, S. M. et al. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28, 265–275 (2003). · DOI · Paper page
- Hunter, M., Ganesan, V. S. & Spence, S. A. Effects of modafinil on prefrontal function and voluntary behaviour in chronic schizophrenia. Schizophr. Bull. 31, 511–512 (2005).
- Spence, S. A., Green, R. D., Wilkinson, I. D. & Hunter, M. D. Modafinil modulates anterior cingulate function in chronic schizophrenia. Br. J. Psychiatry 187, 55–61 (2005). · DOI · Paper page
- Minzenberg, M. J. et al. Response to comment on “modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI”. Science 328, 309 (2010). · DOI
- Pratt, J. A., Winchester, C., Egerton, A., Cochran, S. M. & Morris, B. J. Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. Br. J. Pharmacol. 153, S465–S470 (2008). · DOI · Paper page
- Egerton, A. et al. Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology 198, 37–49 (2008). · DOI
- Bullmore, E. et al. Hierarchical organization of human cortical networks in health and schizophrenia. J. Neurosci. 28, 9239–9248 (2008). · DOI · Paper page
- Micheloyannis, S. et al. Small-world networks and disturbed functional connectivity in schizophrenia. Schizophr. Res. 87, 60–66 (2006). · DOI · Paper page
- Liu, Y. et al. Disrupted small-world networks in schizophrenia. Brain 131, 945–961 (2008). · DOI · Paper page
- Dawson, N., Higham, D., Pratt, J. & Morris, B. Alterations in functional brain network structure induced by subchronic phencyclidine (PCP) treatment parallel those seen in schizophrenia. Schizophr. Res. 117, 234–235 (2010). · doi:10.1016/j.schres.2010.02.349
- Sohal, V. S. Insights into cortical oscillations arising from optogenetic studies. Biol. Psychiatry 71, 1039–1045 (2012). · DOI · Paper page
- Wulff, P. et al. Hippocampal theta rhythm and its coupling with gamma oscillations require fast inhibition onto parvalbumin-positive interneurons. Proc. Natl Acad. Sci. USA 106, 3561–3566 (2009). · DOI · Paper page
- Uhlhaas, P. J. et al. Impaired γ-band synchrony during dysfunctional gestalt perception in schizophrenia. Biol. Psychiatry 59, 5S (2006).
- Jaaro-Peled, H., Ayhan, Y., Pletnikov, M. V. & Sawa, A. Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models. Schizophr. Bull. 36, 301–313 (2010). · DOI · Paper page
- Lawrie, S. M., Hall, J., McIntosh, A. M., Cunningham-Owens, D. G. & Johnstone, E. C. Neuroimaging and molecular genetics of schizophrenia: pathophysiological advances and therapeutic potential. Br. J. Pharmacol. 153, S120–S124 (2008). · DOI
- Weinberger, D. et al. Plenary session — on the matter of neuroimaging in the context of schizophrenia genetics. Schizophr. Res. 117, 109–110 (2010). · doi:10.1016/j.schres.2010.02.023
- Egan, M. F. et al. Effect of COMT Val(108/158) Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl Acad. Sci. USA 98, 6917–6922 (2001). · DOI · Paper page
- Egan, M. F. et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl Acad. Sci. USA 101, 12604–12609 (2004). · DOI · Paper page
- Weinberger, D. R. et al. A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nature Med. 15, 509–518 (2009). · DOI · Paper page
- Callicott, J. et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Neuropsychopharmacology 101, 12604–12609 (2004).
- Straub, R. E. et al. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol. Psychiatry 12, 854–869 (2007). · DOI · Paper page
- McIntosh, A. M. et al. The effects of a neuregulin 1 variant on white matter density and integrity. Mol. Psychiatry 13, 1054–1059 (2008). · DOI · Paper page
- Esslinger, C. et al. Cognitive state and connectivity effects of the genome-wide significant psychosis variant in ZNF804A. Neuroimage 54, 2514–2523 (2011). · DOI
- Potkin, S. G. et al. A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr. Bull. 35, 96–108 (2009). · DOI · Paper page
- Weinberger, D. R. et al. No effect of a common allelic variant in the reelin gene on intermediate phenotype measures of brain structure, brain function, and gene expression. Biol. Psychiatry 68, 105–107 (2010). · DOI
- Bramon, E. et al. Psychosis biological markers and their genetic influences. Schizophr. Res. 117, 217 (2010). · doi:10.1016/j.schres.2010.02.308
- Seeman, P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses 4, 56–73 (2010). · DOI · Paper page
- Nord, M. & Farde, L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci. Ther. 17, 97–103 (2011). · DOI · Paper page
- Miyamoto, S., Duncan, G. E., Marx, C. E. & Lieberman, J. A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79–104 (2005). · DOI · Paper page
- Meltzer, H. Y. & Massey, B. W. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr. Opin. Pharmacol. 11, 59–67 (2011). · DOI · Paper page
- Meltzer, H. Y. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br. J. Psychiatry 168, 23–31 (1996). · DOI · Paper page
- O'Tuathaigh, C. M. P., Kirby, B. P., Moran, P. M. & Waddington, J. L. Mutant mouse models: genotype–phenotype relationships to negative symptoms in schizophrenia. Schizophr. Bull. 36, 271–288 (2010). · DOI
- Wise, R. A. Forebrain substrates of reward and motivation. J. Comp. Neurol. 493, 115–121 (2005). · DOI · Paper page
- Nuechterlein, K. H., Luck, S. J., Lustig, C. & Sarter, M. CNTRICS final task selection: control of attention. Schizophr. Bull. 35, 182–196 (2009). · DOI · Paper page
- Bari, A., Dalley, J. W. & Robbins, T. W. The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nature Protoc. 3, 759–767 (2008). · DOI · Paper page
- Joyce, E. et al. Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study. Br. J. Psychiatry 181, S38–S44 (2002). · DOI · Paper page
- Arguello, P. A. & Gogos, J. A. Cognition in mouse models of schizophrenia susceptibility genes. Schizophr. Bull. 36, 289–300 (2010). · DOI · Paper page
- Marighetto, A. et al. Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents. J. Psychopharmacol. 22, 511–521 (2008). · DOI
- Crawley, J. N. et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 132, 107–124 (1997). · DOI · Paper page
- Koike, H., Arguello, P. A., Kvajo, M., Karayiorgou, M. & Gogos, J. A. Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc. Natl Acad. Sci. USA 103, 3693–3697 (2006). · DOI · Paper page
- Kvajo, M. et al. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc. Natl Acad. Sci. USA 105, 7076–7081 (2008). · DOI · Paper page
- Hikida, T. et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc. Natl Acad. Sci. USA 104, 14501–14506 (2007). · DOI · Paper page
- Niwa, M. et al. Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron 65, 480–489 (2010). · DOI · Paper page
- Pletnikov, M. V. et al. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol. Psychiatry 13, 173–186 (2008). · DOI · Paper page
- Li, W. et al. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc. Natl Acad. Sci. USA 104, 18280–18285 (2007). · DOI · Paper page
- Kuroda, K. et al. Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse. Hum. Mol. Genet. 20, 4666–4683 (2011). · DOI
- Stefansson, H. et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71, 877–892 (2002). · DOI · Paper page
- O'Tuathaigh, C. M. P. et al. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 147, 18–27 (2007). · DOI · Paper page
- Golub, M. S., Germann, S. L. & Lloyd, K. C. K. Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse. Behav. Brain Res. 153, 159–170 (2004). · DOI
- Barros, C. S. et al. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc. Natl Acad. Sci. USA 106, 4507–4512 (2009). · DOI · Paper page
- Siuciak, J. A., McCarthy, S. A., Chapin, D. S. & Martin, A. N. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology 197, 115–126 (2008). · DOI
- Paylor, R. et al. Impaired learning and motor behavior in heterozygous Pafah1b1 (Lis1) mutant mice. Learn. Mem. 6, 521–537 (1999). · DOI · Paper page
- Long, J. M. et al. Behavior of mice with mutations in the conserved region deleted in velocardiofacial/DiGeorge syndrome. Neurogenetics 7, 247–257 (2006). · DOI
- Paylor, R. et al. Mice deleted for the DiGeorge/velocardiofacial syndrome region show abnormal sensorimotor gating and learning and memory impairments. Hum. Mol. Genet. 10, 2645–2650 (2001). · DOI · Paper page
- Drago, J. et al. Altered striatal function in a mutant mouse lacking D1A dopamine receptors. Proc. Natl Acad. Sci. USA 91, 12564–12568 (1994). · DOI · Paper page
- Xu, M. et al. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79, 729–742 (1994). · DOI · Paper page
- Ralph-Williams, R. J., Lehmann-Masten, V., Otero-Corchon, V., Low, M. J. & Geyer, M. A. Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J. Neurosci. 22, 9604–9611 (2002). · DOI · Paper page
- Clifford, J. J. et al. Topographical evaluation of behavioural phenotype in a line of mice with targeted gene deletion of the D-2 dopamine receptor. Neuropharmacology 39, 382–390 (2000). · doi:10.1016/s0028-3908(99)00150-1
- Kellendonk, C., Simpson, E. H. & Kandel, E. R. Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci. 32, 347–358 (2009). · DOI · Paper page
- Babovic, D. et al. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience 155, 1021–1029 (2008). · DOI
- Giros, B., Morice, E., Denis, C. & Nosten-Bertrand, M. Phenotypic expression of the targeted null-mutation in the dopamine transporter gene varies as a function of the genetic background. Eur. J. Neurosci. 20, 120–126 (2004). · DOI · Paper page
- Morice, E. et al. Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia. Neuropsychopharmacology 32, 2108–2116 (2007). · DOI
- Duncan, G. E. et al. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav. Brain Res. 153, 507–519 (2004). · DOI · Paper page
- Miyamoto, Y. et al. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor ε1 subunit. J. Neurosci. 21, 750–757 (2001). · DOI · Paper page
- Boyce-Rustay, J. M. & Holmes, A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 31, 2405–2414 (2006). · DOI · Paper page
- Schmitt, W. B., Deacon, R. M. J., Seeburg, P. H., Rawlins, J. N. P. & Bannerman, D. M. A within-subjects, within-task demonstration of intact spatial reference memory and impaired spatial working memory in glutamate receptor-A-deficient mice. J. Neurosci. 23, 3953–3958 (2003). · DOI · Paper page
- Barkus, C. et al. Do GluA1 knockout mice exhibit behavioral abnormalities relevant to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder? Neuropharmacology 62, 1263–1272 (2011). · DOI · Paper page
- Wiedholz, L. M. et al. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol. Psychiatry 13, 631–640 (2008). · DOI · Paper page
- Sagata, N. et al. Comprehensive behavioural study of GluR4 knockout mice: implication in cognitive function. Genes Brain Behav. 9, 899–909 (2010). · DOI
- Belforte, J. E. et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nature Neurosci. 13, 76–83 (2010). · DOI · Paper page
- Tordera, R. M. et al. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur. J. Neurosci. 25, 281–290 (2007). · DOI · Paper page
- Garcia-Garcia, A. L. et al. Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1. Biol. Psychiatry 66, 275–282 (2009). · DOI
- Chen, Y. W. & Lai, W. S. Behavioral phenotyping of V-Akt murine thymoma viral oncogene homolog 1-deficient mice reveals a sex-specific prepulse inhibition deficit in females that can be partially alleviated by glycogen synthase kinase-3 inhibitors but not by antipsychotics. Neuroscience 174, 178–189 (2011). · DOI
- Lai, W. S. et al. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc. Natl Acad. Sci. USA 103, 16906–16911 (2006). · DOI · Paper page
- Cox, M. M. et al. Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/56J genetic background. Genes Brain Behav. 8, 390–397 (2009). · DOI · Paper page
- Jentsch, J. D. et al. Dysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice. Neuropsychopharmacology 34, 2601–2608 (2009). · DOI
- Papaleo, F. et al. Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol. Psychiatry 17, 85–98 (2012). · DOI · Paper page
- Lipina, T. V. et al. Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. Genes Brain Behav. 9, 777–789 (2010). · DOI
- Hiroi, N. et al. A 200-kb region of human chromosome 22q11.2 confers antipsychotic-responsive behavioral abnormalities in mice. Proc. Natl Acad. Sci. USA 102, 19132–19137 (2005). · DOI
- Duncan, G. E., Moy, S. S., Lieberman, J. A. & Koller, B. H. Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacol. Biochem. Behav. 85, 481–491 (2006). · DOI
- Duncan, G. E., Moy, S. S., Lieberman, J. A. & Koller, B. H. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology 184, 190–200 (2006). · DOI
- Fradley, R. L. et al. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav. Brain Res. 163, 257–264 (2005). · DOI
- Brody, S. A., Conquet, F. & Geyer, M. A. Disruption of prepulse inhibition in mice lacking mGluR1. Eur. J. Neurosci. 18, 3361–3366 (2003). · DOI · Paper page
- Brody, S. A., Conquet, F. & Geyer, M. A. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology 172, 187–195 (2004). · DOI
Cited by
Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function
Piwecka, M., Glažar, P., Hernandez-Miranda, L. R., Memczak, S., Wolf, S. A., Rybak-Wolf, A., Filipchyk, A., Klironomos, F., Cerda Jara, C. A., Fenske, P., et al. (2017) · Science · doi:10.1126/science.aam8526 · Cited by 1,210
Altering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
Developmental timing and critical windows for the treatment of psychiatric disorders
Marín, O. (2016) · Nature Medicine · doi:10.1038/nm.4225 · Cited by 374
Millan, M. J., Fone, K., Steckler, T., & Horan, W. P. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.008 · Cited by 347
Erbb4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes
del Pino, I., García-Frigola, C., Dehorter, N., Brotons-Mas, J. R., Alvarez-Salvado, E., Martínez de Lagrán, M., Ciceri, G., Gabaldón, M. V., Moratal, D., Dierssen, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.010 · Cited by 314
“Despite intensive research, little progress has been made in designing effective treatments for most of these symptoms, in particular for restoring emotional and cognitive functions (Minzenberg and Carter, 2012; Pratt et al., 2012).”
Background
Metadata
- Authors
- Pratt, J., Winchester, C., Dawson, N., & Morris, B.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-06-22
- Volume
- 11
- Issue
- 7
- Pages
- 560-579
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028510688
- Cited by
- 183
- References
- 40
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.